ABSTRACT
<p><b>OBJECTIVE</b>To investigate Epstein-Barr virus(EBV) infection in Hodgkin's lymphoma (HL) of Uygur patients and related clinicopathological characteristics.</p><p><b>METHODS</b>EBV-encoded small RNA (EBER) was detected in 40 cases of HL and 20 cases of lymphoid reactive hyperplasia by in-situ hybridization. Expression of LMP2A in HL was investigated by immunohistochemistry.</p><p><b>RESULTS</b>EBV was detected in 26/40 (65.0%) of HL and 5/20 of lymphoid reactive hyperplasia (P < 0.05). The expression level of EBER showed significant difference among various histological subtypes of HL (P < 0.05) and between patients with and without B symptom (P = 0.02). However, no difference was found in relation to gender, clinical stage and tumor burden. The expression of LMP2A in the mixed cellularity and nodular sclerosis classical HL associated with EBV infection was 57.7% (15/26). Expression of LMP2A was not detected in lymphoid reactive hyperplasia cases.</p><p><b>CONCLUSION</b>Uyghur patients with Hodgkin's lymphoma have a high infection rate of EBV and distinct clinicopathologic characteristics.</p>
Subject(s)
Adolescent , Adult , Child , Child, Preschool , Female , Humans , Male , Middle Aged , Young Adult , China , Ethnology , Epstein-Barr Virus Infections , Herpesvirus 4, Human , Hodgkin Disease , Metabolism , Pathology , Virology , Immunohistochemistry , In Situ Hybridization , Lymphatic Metastasis , Pseudolymphoma , Metabolism , Pathology , Virology , RNA, Viral , Metabolism , Viral Matrix Proteins , MetabolismABSTRACT
<p><b>OBJECTIVE</b>To study the changes of expression of Survivin mRNA, BCRP mRNA and HER-2 mRNA in breast cancer after TE regimen neoadjuvant chemotherapy, and to find biological markers to predict the efficiency of TE regimen neoadjuvant chemotherapy.</p><p><b>METHODS</b>The gene expressions were detected by RT-PCR from 56 breast cancer patients before and after TE regimen neoadjuvant chemotherapy (docetaxel and epirubicin). The relationships between these gene expressions and chemotherapy responses were analyzed.</p><p><b>RESULTS</b>The overall response rate to neoadjuvant chemotherapy was 71.4%, including 8.9% (5/56) with complete response and 62.5% (35/56) with partial response. Pathological complete response was found in 4 cases (7.1%). Stable disease and progression of disease were 23.2% (13/56) and 5.4% (3/56), respectively. The expression of Survivin mRNA after neoadjuvant chemotherapy was 35.7% (20/56), significantly lower than 60.7% (34/56) before neoadjuvant chemotherapy (P = 0.008). The expression of BCRP mRNA after neoadjuvant chemotherapy was 19.6%, significantly lower than 37.5% before neoadjuvant chemotherapy (P = 0.036). The positive rate of HER-2 mRNA expression was 41.1% before the chemotherapy, and reduced to 21.4% after the chemotherapy (P = 0.025). The effective rates of the single positive expression of Survivin mRNA or BCRP mRNA were both lower than that of negative expression (P < 0.05). The level of HER-2 mRNA expression alone was not significantly associated with the effective rate of chemotherapy (P = 0.144). When the expression of all Survivin mRNA, BCRP mRNA and HER-2 mRNA were negative, the effective rate of neoadjuvant chemotherapy was higher than that in patients with positive expression (P = 0.003). The level of Survivin mRNA expression was not significantly associated with BCRP mRNA and HER-2 mRNA (P > 0.05).</p><p><b>CONCLUSION</b>The expression of Survivin in combination with BCRP and HER-2 is associated with clinical response to TE neoadjuvant chemotherapy in breast cancer, and can be used as predictive biomarkers for chemosensitivity of TE regimen neoadjuvant chemotherapy for breast cancer.</p>
Subject(s)
Adult , Aged , Female , Humans , Middle Aged , ATP Binding Cassette Transporter, Subfamily G, Member 2 , ATP-Binding Cassette Transporters , Genetics , Metabolism , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Breast Neoplasms , Drug Therapy , Metabolism , General Surgery , Carcinoma, Ductal, Breast , Drug Therapy , Metabolism , General Surgery , Carcinoma, Lobular , Drug Therapy , Metabolism , General Surgery , Disease Progression , Epirubicin , Inhibitor of Apoptosis Proteins , Genetics , Metabolism , Mastectomy, Radical , Methods , Neoadjuvant Therapy , Neoplasm Proteins , Genetics , Metabolism , RNA, Messenger , Metabolism , Receptor, ErbB-2 , Genetics , Metabolism , Remission Induction , TaxoidsABSTRACT
Objective: To explore the clinicopathologic features of non-Hodgkin' s lymphoma (NHL) patients seen in our hospital in the recent ten years and to discuss the relationship between clinical data and the prognostic factors. Methods: The clinical and pathological features of 1,012 NHL cases were retrospectively analyzed. Results: The main pathological subtypes included 346 (34.1%) cases of diffuse large B-cell lymphoma (DLBCL), 185 (18.3%) cases of peripheral T-cell lymphoma (PTCL), 97 (9.6%) cases of follicular lymphoma (FL), 94 (9.3%) cases of extranodal mucosa-associated lymphoid tissue (MALT), 62 (6.1%) cases of nasal NK/T-cell lymphoma and 47 (4.6%) cases of T-lymphoblastic lymphoma. There were 619 (61.2%) cases classified as nodal lymphoma and 393 (38.8%) cases classified as extranodal lymphoma. For the whole group, the 5-year overall survival (OS) rate was 45.8%. The univariate analysis showed that the clinical stage, performance status (PS), B-symptom, age, tumor size, the serum lactate dehydrogenase (LDH) level, the number of extranodal involvement and IPI were correlated with prognosis of NHL(P＜0.05). The multivariate analysis showed that the source of T cells, Ⅲ/Ⅳ clinical stage, IPI (3～5) and increased LDH were correlated with poor prognosis (P＜0.05). Conclusion: The incidence of NHL in middle-aged people is relatively higher. Extranodal lymphoma and B-cell lymphoma are more frequent in Xinjiang. Immunophenotypes, clinical stages, IPI and the level of LDH expression are closely correlated with prognosis of NHL.